Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.52 |
| ▸ | HNF4A | P41235 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 7/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297956 | 0.88 | ACMSD (0.55) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL3297758 | 0.79 | ACMSD (0.59) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL10420454 | 0.78 | ACMSD (0.69) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL3297396 | 0.75 | HNF4A (0.54) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL3302432 | 0.74 | HNF4A (0.39) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL24407678 | 0.72 | FFAR1 (0.48) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL29810721 | 0.72 | ACMSD (1.00) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL2536183 | 0.72 | ACMSD (1.00) | ACMSDHNF4AXDHSLC22A12MCL1 | |
| SCHEMBL3294710 | 0.71 | HNF4A (0.45) | ACMSDHNF4AKDM4E | |
| SCHEMBL14213143 | 0.70 | ALDH1A1 (0.65) | ACMSDHNF4AXDHSLC22A12MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | ACMSD 3931/4885HNF4A 949/4885XDH 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.